An interdisciplinary comparative framework for antimicrobial efficacy and environmental risk assessment of antibiotics integrating human and environmental health: A case study from patient to river
Integrated Environmental Assessment and Management · 01.11.2026 · 22 (6) · 2033-2046
DOI: 10.1093/inteam/vjag062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrated Environmental Assessment and Management, online erschienen am 16.04.2026. Verfasst von Qiyun Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Environmental Toxicology and Aquatic Ecology, Department of Animal Sciences and Aquatic Ecology, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Water Pollutants, Chemical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: European Union's Horizon Europe research and innovation program, Hercules Foundation, Ghent University Special Research Fund.
Abstract (Originalsprache)
Pharmaceutical residues in aquatic environments are a global concern. The “benign by design” concept seeks to reduce pharmaceutical pollution, among others, through the development of environmentally less persistent derivatives of active pharmaceutical ingredients on the market. Here, we go beyond persistence alone by applying an interdisciplinary framework for comparative environmental risk assessment (ERA) to evaluate a novel fluoroquinolone derivative, ciprofloxacin-hemi (CIP-hemi), versus its conventional counterpart, ciprofloxacin (CIP). The framework integrates antibiotic efficacy, human pharmacokinetics, environmental degradability, and ecotoxicity to nontarget organisms to evaluate the balance of human health needs and environmental protection, combining experimental data with in silico modeling. We show that CIP-hemi, despite its higher overall degradability than CIP, does not exhibit lower risk to aquatic ecosystems at comparable therapeutic efficiency, except in a few specific scenarios where clinically unrealistically high doses are administered to patients. While CIP-hemi has lower predicted environmental concentrations than CIP when the same dose is administered, due to its faster hydrolysis in urine, higher doses of CIP-hemi are required to match the therapeutic efficacy of CIP due to the higher minimum inhibitory concentrations for pathogenic bacteria that are commonly treated with CIP. Consequently, even though CIP-hemi has higher predicted no-effect concentrations for aquatic ecosystems (201 ng L−1) and antimicrobial resistance selection in aquatic environments (56,000 ng L−1) than CIP (22 and 79 ng L−1, respectively), the higher doses needed generally cause higher environmental risks. Ciprofloxacin-hemi could achieve lower risk than CIP for antimicrobial resistance selection in some scenarios but only when administered intravenously and at unrealistically high doses. On the basis of this comparative ERA, we conclude that focusing on higher degradability alone is insufficient in searching for “greener” derivatives of existing antibiotics. Rather, an interdisciplinary framework is needed that integrates degradability, therapeutic efficacy, human pharmacokinetics, and ERA to improve the development of environmentally safer pharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Environmental Toxicology and Aquatic Ecology, Department of Animal Sciences and Aquatic Ecology, Ghent University, Ghent, Belgium.
- Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
- Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
- Centre for Safety of Substances and Products, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
- Radboud Institute for Biological and Environmental Sciences, Radboud University Nijmegen, Nijmegen, the Netherlands.
- Institute of Sustainable Chemistry, Leuphana University Lüneburg, Lüneburg, Germany.
ORCID-Profile: Qiyun Zhang, Caroline T A Moermond, Kristof Demeestere
Förderung
- European Union's Horizon Europe research and innovation program
- Hercules Foundation
- Ghent University Special Research Fund
- European Union’s Horizon Europe research and innovation program
Zitieren
APA
Zhang, Q., De Sutter, P. J., Amorim, J. F., Järvinen, P., Moermond, C. T. A., Suk, M., Kümmerer, K., Demeestere, K., Sikanen, T. M., & De Schamphelaere, K. A. C. (2026). An interdisciplinary comparative framework for antimicrobial efficacy and environmental risk assessment of antibiotics integrating human and environmental health: A case study from patient to river. Integrated Environmental Assessment and Management, 22(6), 2033-2046. https://doi.org/10.1093/inteam/vjag062
Vancouver
Zhang Q, De Sutter PJ, Amorim JF, Järvinen P, Moermond CTA, Suk M, et al. An interdisciplinary comparative framework for antimicrobial efficacy and environmental risk assessment of antibiotics integrating human and environmental health: A case study from patient to river. Integrated Environmental Assessment and Management. 2026;22(6):2033-2046. doi:10.1093/inteam/vjag062
BibTeX
@article{Zhang2026,
author = {Zhang, Qiyun and De Sutter, Pieter-Jan and Amorim, Jéssica F and Järvinen, Päivi and Moermond, Caroline T A and Suk, Morten and Kümmerer, Klaus and Demeestere, Kristof and Sikanen, Tiina M and De Schamphelaere, Karel A C},
title = {An interdisciplinary comparative framework for antimicrobial efficacy and environmental risk assessment of antibiotics integrating human and environmental health: A case study from patient to river},
journal = {Integrated Environmental Assessment and Management},
year = {2026},
volume = {22},
number = {6},
pages = {2033--2046},
doi = {10.1093/inteam/vjag062}
}
EUVIMED